# Kite, A Gilead Company: Phase 3 study in Newly Diagnosed Multiple Myeloma (600 participants)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Kite, A Gilead Company |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma |
| NCT ID | NCT07887672 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Newly Diagnosed Multiple Myeloma |
| Intervention types | drug |
| Target enrollment | 600 |
| Posted | 2026-10-21 |
| Planned start | 2027-01 |
| Event | Newly registered study |
| Event date | 2026-10-21 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 600 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07887672). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.